Profile
| Metric | Value |
|---|---|
| Full Name | Amylyx Pharmaceuticals, Inc. |
| Ticker | NASDAQ: AMLX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | amylyx.com |
| Employees | 123 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $16.92 | |
| Price, 1D Change | +2.24% | |
| Market Cap | $2B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.88 | |
| Revenue | $87M | |
| Revenue, 1Y Change | -77.06% | |
| EPS | -$4.43 | |
| EPS, 1Y Change | -728.99% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$4.43 | |
| EPS Estimate | -$1.53 | |
| EPS Est. Change | +65.51% | |
| Revenue | $87.37M | |
| Revenue Estimate | - | |
| Revenue Est. Change | - | |
| Current Price | $16.92 | |
| Price Target | - | $20.00 |
| Price Tgt. Change | - | +18.20% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $0.90 | $0.70 | -21.78% | |
| -$4.30 | -$4.43 | -3.10% | |
| -$1.53 | N/A | +65.51% | |
| -$1.25 | N/A | +71.78% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $379.74M | $380.79M | +0.28% | |
| $88.03M | $87.37M | -0.75% | |
| - | N/A | - | |
| - | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +390.43% | |
| Price, 3Y | -54.11% | |
| Market Cap, 1Y | +509.65% | |
| Market Cap, 3Y | -24.23% | |
| Revenue, 1Y | -77.06% | |
| Revenue, 3Y | +30,556.49% | |
| EPS, 1Y | -728.99% | |
| EPS, 3Y | -191.40% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $16.92 | |
| SMA 200 | $9.67 | |
| SMA 200 vs Price | -42.87% | |
| SMA 50 | $13.18 | |
| SMA 50 vs Price | -22.09% | |
| Beta | 0.88 | |
| ATR | $0.94 | |
| 14-Day RSI | 76.90 | |
| 10-Day Volatility | 92.79% | |
| 1-Year Volatility | 75.06% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $87.37M | |
| EPS | -$4.43 | |
| Gross Profit | -$38.17M | |
| Gross Margin | -43.68% | |
| Operating Profit | -$291.88M | |
| Operating Margin | -292.63% | |
| Net Income | -$301.74M | |
| Net Margin | -345.36% | |
| EBITDA | -$290.98M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.01 | |
| Current Ratio | 6.67 | |
| Quick Ratio | 6.67 | |
| - | ||
| F-Score | - | |
| Altman Z-Score | 30.71 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | -2,794.21 | |
| PB Ratio | 5.60 | |
| EV/EBITDA | -9.70 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $164.77M | |
| Cash & Equivalents | $77.39M | |
| Total Assets | $193.63M | |
| Current Assets | $189.43M | |
| Total Liabilities | $28.87M | |
| Current Liabilities | $28.41M | |
| Total Debt | $1.98M | |
| Short Term Debt | $1.52M | |
| Accounts Payable | $2.94M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $379.25M | |
| Operating Expenses | $254.62M | |
| Cost Of Goods Sold | $125.54M | |
| SG&A | $114.33M | |
| D&A | $904.00K | |
| Interest Expense | $0.00 | |
| Income Tax | -$393.00K |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$167.65M | |
| CFI | $75.65M | |
| CFF | $348.00K | |
| Capex | $36.36M | |
| Free Cash Flow | -$167.80M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| HC Wainwright & Co. | → | |
| Citigroup | → | |
| Baird | → | |
| B of A Securities | → | |
| Goldman Sachs | → | |
| Guggenheim | → | |
| B of A Securities | → | |
| Guggenheim | ||
| Citigroup | ||
| Mizuho | → |
Analyst sentiment
Institutional ownership
Screeners with AMLX
FAQ
What is the ticker symbol for Amylyx Pharmaceuticals, Inc.?
The ticker symbol for Amylyx Pharmaceuticals, Inc. is NASDAQ:AMLX
Does Amylyx Pharmaceuticals, Inc. pay dividends?
No, Amylyx Pharmaceuticals, Inc. does not pay dividends
What sector is Amylyx Pharmaceuticals, Inc. in?
Amylyx Pharmaceuticals, Inc. is in the Healthcare sector
What industry is Amylyx Pharmaceuticals, Inc. in?
Amylyx Pharmaceuticals, Inc. is in the Biotechnology industry
What country is Amylyx Pharmaceuticals, Inc. based in?
Amylyx Pharmaceuticals, Inc. is headquartered in United States
When did Amylyx Pharmaceuticals, Inc. go public?
Amylyx Pharmaceuticals, Inc. initial public offering (IPO) was on January 7, 2022
Is Amylyx Pharmaceuticals, Inc. in the S&P 500?
No, Amylyx Pharmaceuticals, Inc. is not included in the S&P 500 index
Is Amylyx Pharmaceuticals, Inc. in the NASDAQ 100?
No, Amylyx Pharmaceuticals, Inc. is not included in the NASDAQ 100 index
Is Amylyx Pharmaceuticals, Inc. in the Dow Jones?
No, Amylyx Pharmaceuticals, Inc. is not included in the Dow Jones index
When was Amylyx Pharmaceuticals, Inc. last earnings report?
Amylyx Pharmaceuticals, Inc.'s most recent earnings report was on November 6, 2025
When does Amylyx Pharmaceuticals, Inc. report earnings?
The next expected earnings date for Amylyx Pharmaceuticals, Inc. is March 3, 2026
Data Sources & References
- AMLX Official Website amylyx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1658551/000119312525268059/0001193125-25-268059-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1658551/000095017025031309/0000950170-25-031309-index.htm
- AMLX Profile on Yahoo Finance finance.yahoo.com/quote/AMLX
- AMLX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/amlx